GlassScriptPhysician profile
Kaylin N Spell
NPI 1144610056
$1,188.15
in general payments reported to CMS, 2019-2025
23 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $198 · 2022: $178 · 2023: $283 · 2024: $254 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $223.65 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $119.54 | 2022-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $93.97 | 2021-2023 | Xarelto, Spravato |
| Abbott Laboratories | $92.93 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $91.43 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $89.99 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $61.22 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.40 | 2021-2024 | |
| Amgen INC. | $46.97 | 2023-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $42.00 | 2025 | |
| Abbvie INC. | $33.18 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.54 | 2021-2024 | Xifaxan, Trulance |
| Actelion Pharmaceuticals US, INC. | $29.44 | 2025 | Uptravi, Opsumit |
| Astellas Pharma US INC | $25.38 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $22.11 | 2025 | Gemtesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $21.96 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $20.90 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.46 | 2021 | |
| Glaxosmithkline, LLC. | $14.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.77 | 2023 | Fasenra |
| Novartis Pharmaceuticals Corporation | $14.75 | 2023 | |
| Alexion Pharmaceuticals, INC. | $13.16 | 2022 | |
| Horizon Therapeutics Plc | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylin Spell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.